Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 12/20 | 0.44 |
| ▸ | RARG | P13631 | 12/20 | 0.44 |
| ▸ | RARA | P10276 | 10/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.42 |
| ▸ | RXRA | P19793 | 3/20 | 0.41 |
| ▸ | HNF4A | P41235 | 2/20 | 0.41 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9318560 | 0.86 | RARB (0.56) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL9526910 | 0.83 | RARB (0.37) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL4300903 | 0.80 | RARB (0.66) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL30061258 | 0.80 | RARB (0.66) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL1320433 | 0.80 | CYP3A4 (0.65) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL9333999 | 0.78 | RARB (0.56) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL9334964 | 0.78 | GABRP (0.37) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6037049 | 0.76 | RARB (0.67) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6668166 | 0.76 | CYP26A1 (0.46) | RARBRARGRARACYP3A4CYP26A1 | |
| SCHEMBL6664117 | 0.75 | CYP26A1 (0.52) | RARBRARGRARACYP3A4CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026951-A1 | Methods of therapeutic treatment using retinoids with reduced drug interaction | ALLERGAN, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| US-20050027003-A1 | Methods of therapeutic treatment using retinoids with reduced side effects | ALLERGAN, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| US-20050026957-A1 | Methods of treating nodulocystic acne | ALLERGAN, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| US-20050026949-A1 | Methods of therapeutic treatment using amounts of retinoids without regard to body weight | ALLERGAN, INC. (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026949-A1 | Methods of therapeutic treatment using amounts of retinoids without regard to body weight | RARG, RXRG, RARA | RARB 4/4885RARG 1/4885RARA 3/4885 |
| US-20050026951-A1 | Methods of therapeutic treatment using retinoids with reduced drug interaction | RXRA, RARA, RARB | RARB 3/4885RARG 5/4885RARA 2/4885 |
| US-20050026957-A1 | Methods of treating nodulocystic acne | RARA, RARB, RARG | RARB 2/4885RARG 3/4885RARA 1/4885 |
| US-20050027003-A1 | Methods of therapeutic treatment using retinoids with reduced side effects | RARA, RARB, RARG | RARB 2/4885RARG 3/4885RARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.